Jewell, A.; McMahon, M.; Khabele, D. Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer. Cancers2018, 10, 296.
Jewell, A.; McMahon, M.; Khabele, D. Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer. Cancers 2018, 10, 296.
Jewell, A.; McMahon, M.; Khabele, D. Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer. Cancers2018, 10, 296.
Jewell, A.; McMahon, M.; Khabele, D. Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer. Cancers 2018, 10, 296.
Abstract
Heated intraperitoneal chemotherapy (HIPEC) has several potential benefits. Higher doses of chemotherapy can be used with HIPEC because the plasma-peritoneal barrier results in little absorption into the blood stream. HIPEC offers higher peritoneal penetration in comparison to an intravenous (IV) regimen and does not have the traditional normothermic intraperitoneal (IP) regimen limitation of post-operative adhesions. Hyperthermia itself has cytotoxic effects and can potentiate antineoplastic effects of chemotherapy in part by increasing the depth of tumor penetration by up to 3 mm. For the treatment of ovarian cancer, HIPEC has been evaluated in the recurrent setting with secondary cytoreduction. Recent studies, including a prospective trial, have evaluated its role in primary management of ovarian cancer. This review summarizes previous and ongoing studies regarding the use of HIPEC in the management of ovarian cancer.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
